Investor Information For IntraOp Medical
Invest in saving lives with Mobetron
IntraOp Medical Corporation was founded in April 1993 to develop, manufacture, market and service the Mobetron, a mobile electron beam system designed for intraoperative electron radiotherapy (IOERT) treatment of cancer cells and malignant tumor beds.
In the past, cancer patients have only undergone the conventional intraoperative radiotherapy (IORT) that Mobetron is capable of, but Mobetron’s IOERT superiority and patented technology is changing the way cancer patients are treated and improving survival and recurrence rates all over the world.
Mobetron makes IOERT less time-consuming, less costly and less risky to administer. And international hospitals and treatment centers are quickly realizing Mobetron’s advantages as market opportunities grow all over the world.
The Mobetron Advantages
- Small and lightweight
- No additional shielding
- Fits in existing ORs, hallways and standard elevators
- Can be shared between multiple ORs
- Eliminates need for heroic transport and dedicated ORs
Market Advantages
- Mobetron is the technology leader.
- There are 3,925 institutions/treatment centers worldwide that would benefit from IOERT (a $5 billion target market).
- Mobetron has a 20% IORT market share and a 60% market share for IOERT.
- IntraOp has a $1 billion opportunity assuming 20% market penetration.
- Mobetron is already installed at most cancer centers of excellence in U.S., Europe and China.
Mobetron and the rest of our products are part of a cancer treatment solution that is improving the quality of life for cancer patients going through IORT and IOERT. When you invest in Mobetron, you’re not just investing in revolutionary cancer treatment technology. You’re investing in saving lives worldwide.
Fill out the contact form to find out more about IntraOp Medical and Mobetron investment opportunities:
IntraOp Medical is incorporated in the State of Nevada. The stock is traded on the bulletin board (IOPM.ob).
